☰

Reena S. Cecchini, Ph.D.

Affiliations: 
2012 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Public Health, Epidemiology
Google:
"Reena Cecchini"
Cross-listing: PHTree

Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Jane A. Cauley grad student 2012 University of Pittsburgh
 (Issues in breast cancer prevention: Body mass index, breast density, and fractures.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Henry NL, Kim S, Hays RD, et al. (2022) Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30. Npj Breast Cancer. 8: 123
Henry NL, Kim S, Hays RD, et al. (2021) Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100910
Ganz PA, Cecchini RS, Fehrenbacher L, et al. (2021) NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. Npj Breast Cancer. 7: 55
Basik M, Cecchini RS, Santos JFDL, et al. (2020) Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery Cancer Research. 80
Fehrenbacher L, Cecchini RS, Geyer CE, et al. (2019) NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901455
Vicini FA, Cecchini RS, White JR, et al. (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet (London, England)
de Azambuja E, Ponde N, Procter M, et al. (2019) A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Research and Treatment
Ganz PA, Cecchini RS, White JR, et al. (2019) Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Clinical Oncology. 37: 508-508
Vicini F, Cecchini R, White J, et al. (2019) Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer Cancer Research. 79
Pogue-Geile KL, Wang Y, Feng H, et al. (2019) Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 Cancer Research. 79: 4064-4064
See more...